I checked the other thread, apparently
I never dropped of the url--but here it is:
biomednet.com
You may have to register on your way in at biomednet.com
Before you spend all your money on a single gene therapy
company, you might want to look into some of the other
players. For now the traders are taking Avigen up up
and away, and that's great...but I'd want to own several.
Ideally, you would want a more specialized biotech fund,
but I've not found it. Janus should start up something
like that, but they'd probably just fall in love with
Amgen like all the other funds anyway.
Well, getting back on topic...these CO review articles
each have an extensive bibliograpy--the one for which
I gave the url sites 64 papers...and several are marked
'of special' or 'outstanding interest'.
Here are two of three marked as of outstanding interest".
Jooss K, Yang Y, Fisher KJ, Wilson JM:
Transduction of dendritic cells by DNA viral vectors directs the immune response to transgene products in muscle fibers.
J Virol 1998, 72: 4212–4223. [Full text] [MEDLINE] [Cited by]
Rabinowitz and Samulski write...
This is an excellent paper describing the immunologic state in reponse to rAAVlacZ transduction in muscle cells. It asks the question why rAAV fails to elicit an immune response when other vector systems do. Adoptive transfer experiments clearly indicate that antigen-presenting cells activated by adenovirus lacZ will eliminate lacZ expressing muscle cells previously infected with rAAVlacZ.
•• Xiao X, Li J, Samulski RJ:
Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus.
J Virol 1998, 72: 2224–2232. [Full text] [MEDLINE] [Cited by]
the authors write:
One of the disadvantages in the production of rAAV is the contaminating adenovirus by-product. This paper brings together new production techniques that result in high titer adenovirus free rAAV.
The first one caught my eye--Wilson is president of asgt,
see asgt.org for more, here is his presidential address to
the ASGT:
asgt.org
Have fun with your research, stick to 'mad money',
and don't put all your eggs in one basket...and
as always, just my two cents--you get what you pay
for! (that was all the disclaimer cliches I could
jam in).
If you want to familiarize yourself with some of
the names in the area of Gene Therapy, go to this
link, also at asgt:
asgt.org |
